MarketLens

What's Driving Telix's Latest FDA Resubmission for Pixclara®

7 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What's Driving Rocket Pharmaceuticals' Latest FDA Review for KRESLADI

7 months ago

What's Driving the Latest Market Volatility

7 months ago

What Does Ultragenyx's Latest FDA Clearance Mean for Investors

6 months ago

What's Driving Basilea's Latest Surge

7 months ago

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics resubmitted its tabelecleucel Biologics License Application to the FDA, seeking approval for the allogeneic EBV T-cell therapy. The resubmission restarts the regulatory review cl...

ATRA

Stock News•3 weeks ago

Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement

Telix Pharmaceuticals kept a Buy rating after the FDA approved PIXCLARA, the first FET-PET imaging agent for glioma, and Phase 3 programs for TLX250-Tx and TLX591-Tx advanced with FDA alignment.

TLX

Stock News•2 months ago

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Radiopharm Theranostics' RAD204 achieved a confirmed durable partial response at the highest dose level (90mCi) in a Phase 1 trial, with one patient progression-free beyond seven months.

RADX